Coexistence of primary AL amyloidosis and POEMS syndrome: Efficacy of melphalan‐dexamethasone and role of biochemical markers in monitoring the diseases course

Abstract

American Journal of HematologyVolume 85, Issue 2 p. 131-132 LetterFree Access Coexistence of primary AL amyloidosis and POEMS syndrome: Efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course† Fausto Adami, Corresponding Author Fausto Adami [email protected] Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, Padova University School of Medicine, Padova, ItalyDepartment of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, Padova University School of Medicine, Via Giustiniani 2, Padova 35128, ItalySearch for more papers by this authorChiara Briani, Chiara Briani Department of Neurosciences, Padova University School of Medicine, Padova, ItalySearch for more papers by this authorGianni Binotto, Gianni Binotto Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, Padova University School of Medicine, Padova, ItalySearch for more papers by this authorSara Altinier, Sara Altinier Department of Laboratory Medicine, Padova University School of Medicine, Padova, ItalySearch for more papers by this authorGiuseppe Tarantini, Giuseppe Tarantini Department of Cardiac, Thoracic and Vascular Sciences, Padova University School of Medicine, Padova, ItalySearch for more papers by this authorGianpietro Semenzato, Gianpietro Semenzato Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, Padova University School of Medicine, Padova, ItalySearch for more papers by this author Fausto Adami, Corresponding Author Fausto Adami [email protected] Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, Padova University School of Medicine, Padova, ItalyDepartment of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, Padova University School of Medicine, Via Giustiniani 2, Padova 35128, ItalySearch for more papers by this authorChiara Briani, Chiara Briani Department of Neurosciences, Padova University School of Medicine, Padova, ItalySearch for more papers by this authorGianni Binotto, Gianni Binotto Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, Padova University School of Medicine, Padova, ItalySearch for more papers by this authorSara Altinier, Sara Altinier Department of Laboratory Medicine, Padova University School of Medicine, Padova, ItalySearch for more papers by this authorGiuseppe Tarantini, Giuseppe Tarantini Department of Cardiac, Thoracic and Vascular Sciences, Padova University School of Medicine, Padova, ItalySearch for more papers by this authorGianpietro Semenzato, Gianpietro Semenzato Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Section, Padova University School of Medicine, Padova, ItalySearch for more papers by this author First published: 29 October 2009 https://doi.org/10.1002/ajh.21581Citations: 3 † Conflict of interest: Nothing to report. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Kuwabara S. New strategy of treatment for POEMS syndrome: Autologous peripheral blood stem cell transplantation and thalidomide therapy. Brain Nerve 2008; 60: 627– 633. 2 Dispenzieri A. POEMS syndrome. Blood Rev 2007; 21: 285– 299. 3 Kuwabara S,Dispenzieri A,Arimura K, et al. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev 2008; 4: CD006828. 4 Dispenzieri A,Kyle R,Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215– 224. 5 Iwasaki T,Hamano T,Ogata A, et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Hematol 2002; 116: 796– 802. 6 Soubrier M,Dubost JJ,Serre AF, et al. Growth factors in POEMS syndrome: Evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum 1997; 40: 786– 787. 7 Scarlato M,Previtali SC,Carpo M, et al. Polyneuropathy in POEMS syndrome: Role of angiogenic factors in the pathogenesis. Brain 2005; 128: 1911– 1920. 8 Nobile-Orazio E,Terenghi F,Giannotta C, et al. Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. Neurology 2009; 72: 1024– 1026. 9 Patier JL,Pinilla A,Rodriguez-Posada A, et al. Primary amyloidosis associated with osteosclerotic myeloma. Rev Clin Esp 2003; 203: 162– 163. 10 Briani C,Scarlato M,Pavan A, et al. Polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes: Not always a POEMS syndrome. Hematologica 2006; 91: ECR10. 11 Watanabe O,Maruyama I,Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998; 21: 1390– 1397. 12 Merlini G,Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520– 2530. 13 Palladini G,Perfetti V,Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936– 2938. Citing Literature Volume85, Issue2February 2010Pages 131-132 ReferencesRelatedInformation